SFY0 Stock Chart & Stats
€2.42
€0.00(0.00%)
At close: 4:00 PM EST
€2.42
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.42 - €2.42
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.72M
Enterprise Value-€1.10M
Total Cash (Recent Filing)€14.43M
Total Debt (Recent Filing)€3.69M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 12, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding45,892,670
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.18Price Target Upside-9.75% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.19
Revenue Forecast (FY)€25.25M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress / Trial StartRegulatory authorization to start VIRAGE2 materially de-risks development timing for VCN-01 in pancreatic cancer and enables generation of tolerability and dosing data needed to refine a regimen toward a potential pivotal Phase 3. This strengthens the clinical development pathway and partnerability over the medium term.
Positive Clinical Data & MechanismPeer-reviewed Phase 1 and Phase 2b data showing improved overall survival, PFS and translational biomarkers support VCN-01's mechanism of stromal degradation and immune remodeling. Durable biological signal increases likelihood of regulatory and commercial interest, underpinning long-term clinical value creation.
Low Financial LeverageLow debt levels provide balance sheet flexibility for a cash-burning clinical-stage biotech, reducing near-term solvency risk and preserving strategic options (equity raises, partnerships). Manageable leverage makes it easier to pursue development milestones without large fixed servicing costs.
Bears Say
Sustained Cash BurnConsistent negative operating and free cash flow indicates the company will remain reliant on external financing to fund trials and operations. Persistent burn increases dilution risk, pressures management to secure capital at unpredictable timing, and constrains reinvestment planning over the coming months.
Deep & Persistent LossesHeavy, recurring operating losses and minimal product revenue reflect a lack of commercial scale. Sustained negative profitability erodes equity and investor value over time, complicates long-term planning, and increases dependence on milestone-based partnerships or dilutive financings to sustain development.
Financing & Governance UncertaintyRepeated quorum failures and postponed warrant approvals create procedural uncertainty around planned equity issuances. This can delay access to committed financing, prolong fundraising timelines, and raise execution risk for meeting near-term cash needs and trial funding commitments.
Theriva Biologics News
SFY0 FAQ
What was Theriva Biologics, Inc.’s price range in the past 12 months?
Theriva Biologics, Inc. lowest stock price was €2.42 and its highest was €2.42 in the past 12 months.
What is Theriva Biologics, Inc.’s market cap?
Theriva Biologics, Inc.’s market cap is €9.72M.
When is Theriva Biologics, Inc.’s upcoming earnings report date?
Theriva Biologics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 31 days.
How were Theriva Biologics, Inc.’s earnings last quarter?
Theriva Biologics, Inc. released its earnings results on May 05, 2026. The company reported -€0.044 earnings per share for the quarter, the consensus estimate of -€0.044 by €0.
Is Theriva Biologics, Inc. overvalued?
According to Wall Street analysts Theriva Biologics, Inc.’s price is currently Overvalued.
Does Theriva Biologics, Inc. pay dividends?
Theriva Biologics, Inc. does not currently pay dividends.
What is Theriva Biologics, Inc.’s EPS estimate?
Theriva Biologics, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Theriva Biologics, Inc. have?
Theriva Biologics, Inc. has 45,892,670 shares outstanding.
What happened to Theriva Biologics, Inc.’s price movement after its last earnings report?
Theriva Biologics, Inc. reported an EPS of -€0.044 in its last earnings report, expectations of -€0.044. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Theriva Biologics, Inc.?
Currently, no hedge funds are holding shares in DE:SFY0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theriva Biologics, Inc.
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
SFY0 Stock 12 Month Forecast
Average Price Target
€2.18
▼(-9.75% Downside)
Technical Analysis
Options Prices
Currently, No data available
---